Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Current state of pediatric sarcoma biology and opportunities for future discovery: A report from the sarcoma translational research workshop.
Hingorani P, Janeway K, Crompton BD, Kadoch C, Mackall CL, Khan J, Shern JF, Schiffman J, Mirabello L, Savage SA, Ladanyi M, Meltzer P, Bult CJ, Adamson PC, Lupo PJ, Mody R, DuBois SG, Parsons DW, Khanna C, Lau C, Hawkins DS, Randall RL, Smith M, Sorensen PH, Plon SE, Skapek SX, Lessnick S, Gorlick R, Reed DR. Hingorani P, et al. Cancer Genet. 2016 May;209(5):182-94. doi: 10.1016/j.cancergen.2016.03.004. Epub 2016 Apr 5. Cancer Genet. 2016. PMID: 27132463 Free PMC article. Review.
Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children's Oncology Group (COG) New Agents for Ewing Sarcoma Task Force.
Bailey K, Cost C, Davis I, Glade-Bender J, Grohar P, Houghton P, Isakoff M, Stewart E, Laack N, Yustein J, Reed D, Janeway K, Gorlick R, Lessnick S, DuBois S, Hingorani P. Bailey K, et al. Among authors: hingorani p. F1000Res. 2019 Apr 15;8:F1000 Faculty Rev-493. doi: 10.12688/f1000research.18139.1. eCollection 2019. F1000Res. 2019. PMID: 31031965 Free PMC article. Review.
Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group.
Roberts RD, Lizardo MM, Reed DR, Hingorani P, Glover J, Allen-Rhoades W, Fan T, Khanna C, Sweet-Cordero EA, Cash T, Bishop MW, Hegde M, Sertil AR, Koelsche C, Mirabello L, Malkin D, Sorensen PH, Meltzer PS, Janeway KA, Gorlick R, Crompton BD. Roberts RD, et al. Among authors: hingorani p. Cancer. 2019 Oct 15;125(20):3514-3525. doi: 10.1002/cncr.32351. Epub 2019 Jul 29. Cancer. 2019. PMID: 31355930 Free PMC article. Review.
Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Force.
Whittle SB, Offer K, Roberts RD, LeBlanc A, London C, Majzner RG, Huang AY, Houghton P, Alejandro Sweet Cordero E, Grohar PJ, Isakoff M, Bishop MW, Stewart E, Slotkin EK, Greengard E, Borinstein SC, Navid F, Gorlick R, Janeway KA, Reed DR, Hingorani P. Whittle SB, et al. Among authors: hingorani p. Pediatr Blood Cancer. 2021 Sep;68(9):e29188. doi: 10.1002/pbc.29188. Epub 2021 Jun 16. Pediatr Blood Cancer. 2021. PMID: 34137164 Free PMC article.
HER2-Targeted Therapy in Osteosarcoma.
Gill J, Hingorani P, Roth M, Gorlick R. Gill J, et al. Among authors: hingorani p. Adv Exp Med Biol. 2020;1257:55-66. doi: 10.1007/978-3-030-43032-0_5. Adv Exp Med Biol. 2020. PMID: 32483730 Review.
Oncolytic viruses for potential osteosarcoma therapy.
Hingorani P, Sampson V, Lettieri C, Kolb EA. Hingorani P, et al. Adv Exp Med Biol. 2014;804:259-83. doi: 10.1007/978-3-319-04843-7_14. Adv Exp Med Biol. 2014. PMID: 24924179 Review.
Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors.
Mascarenhas L, Ogawa C, Laetsch TW, Weigel BJ, Bishop MW, Krystal J, Borinstein SC, Slotkin EK, Muscal JA, Hingorani P, Levy DE, Mo G, Shahir A, Wright J, DuBois SG. Mascarenhas L, et al. Among authors: hingorani p. Cancer Med. 2021 Feb;10(3):843-856. doi: 10.1002/cam4.3658. Epub 2021 Jan 20. Cancer Med. 2021. PMID: 33474828 Free PMC article. Clinical Trial.
A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children's Oncology Group.
Isakoff MS, Goldsby R, Villaluna D, Krailo MD, Hingorani P, Collier A, Morris CD, Kolb EA, Doski JJ, Womer RB, Gorlick R, Janeway KA. Isakoff MS, et al. Among authors: hingorani p. Pediatr Blood Cancer. 2019 Feb;66(2):e27524. doi: 10.1002/pbc.27524. Epub 2018 Oct 30. Pediatr Blood Cancer. 2019. PMID: 30378256 Free PMC article. Clinical Trial.
59 results